Macquarie Group
ABEO icon

Macquarie Group’s Abeona Therapeutics ABEO Stock Holding History

Macquarie Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-760
Closed -$6 – 1887
2024
Q1 		$6 Buy
+760
New +$4.82K ﹤0.01% 1759
2021
Q1 		– Sell
-4,004
Closed -$157K – 2461
2020
Q4 		$157K Buy
+4,004
New +$136K ﹤0.01% 1744
2019
Q1 		– Sell
-20
Closed -$4K – 1640
2018
Q4 		$4K Hold
20
– – ﹤0.01% 2124
2018
Q3 		$6K Sell
20
-24
-55% -$8.51K ﹤0.01% 2045
2018
Q2 		$18K Buy
+44
New +$19.2K ﹤0.01% 2070
2018
Q1 		– Sell
-24
Closed -$10K – 2147
2017
Q4 		$10K Buy
+24
New +$9.93K ﹤0.01% 2258

Other funds holding ABEO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Macquarie Group's ABEO Position: Q2 2024 in Review

Macquarie Group sold out of Abeona Therapeutics (ABEO) in Q2 2024, closing a stake of 760 shares — an estimated $6 sold.

Macquarie Group first reported a position in ABEO in Q4 2017 and held it in 6 quarters. The position peaked at $157K in Q4 2020. 48 funds tracked by Wall St. Rank hold ABEO as of Q2 2024.

  • Macquarie Group reported no remaining Abeona Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 760 Abeona Therapeutics shares in Q2 2024, an estimated $6.
  • Macquarie Group first reported a position in Abeona Therapeutics in Q4 2017 and held it in 6 quarters.
  • Macquarie Group's Abeona Therapeutics position peaked at $157K in Q4 2020.
  • 48 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.